adrenomedullin   Click here for help

GtoPdb Ligand ID: 683

Abbreviated name: AM
Immunopharmacology Ligand
Compound class: Endogenous peptide in human, mouse or rat
Comment: Adrenomedullin is 52 amino acid peptide which is mainly expressed in endothelial and smooth muscle cells. It acts as a vasodilatory peptide and it is known to regulate endothelial barrier function and vascular tone. Evidence from animal models indicates that it is a key player in the development of sepsis-associated hemodynamic and microcirculatory disorders.
Species: Human
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Aiyar N, Disa J, Pullen M, Nambi P. (2001)
Receptor activity modifying proteins interaction with human and porcine calcitonin receptor-like receptor (CRLR) in HEK-293 cells.
Mol Cell Biochem, 224 (1-2): 123-33. [PMID:11693189]
2. Fraser NJ, Wise A, Brown J, McLatchie LM, Main MJ, Foord SM. (1999)
The amino terminus of receptor activity modifying proteins is a critical determinant of glycosylation state and ligand binding of calcitonin receptor-like receptor.
Mol Pharmacol, 55: 1054-1059. [PMID:10347248]
3. Geven C, Pickkers P. (2018)
The mechanism of action of the adrenomedullin-binding antibody adrecizumab.
Crit Care, 22 (1): 159. [PMID:29895302]
4. Geven C, van Lier D, Blet A, Peelen R, Ten Elzen B, Mebazaa A, Kox M, Pickkers P. (2018)
Safety, tolerability and pharmacokinetics/pharmacodynamics of the adrenomedullin antibody adrecizumab in a first-in-human study and during experimental human endotoxaemia in healthy subjects.
Br J Clin Pharmacol, 84 (9): 2129-2141. [PMID:29856470]
5. Hay DL, Christopoulos G, Christopoulos A, Poyner DR, Sexton PM. (2005)
Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes.
Mol Pharmacol, 67 (5): 1655-65. [PMID:15692146]
6. Kuwasako K, Kitamura K, Nagoshi Y, Eto T. (2003)
Novel calcitonin-(8-32)-sensitive adrenomedullin receptors derived from co-expression of calcitonin receptor with receptor activity-modifying proteins.
Biochem Biophys Res Commun, 301 (2): 460-4. [PMID:12565884]
7. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, Foord SM. (1998)
RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor.
Nature, 393 (6683): 333-9. [PMID:9620797]
8. Struck J, Hein F, Karasch S, Bergmann A. (2013)
Epitope specificity of anti-Adrenomedullin antibodies determines efficacy of mortality reduction in a cecal ligation and puncture mouse model.
Intensive Care Med Exp, 1 (1): 22. [PMID:26266791]